25 completed. 25 Phase 2, 4 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Completed 25 |
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 3 | Completed 3 |
Follow Systemic Vasculitis: new trials by email Literature Review of Systemic Vasculitis trials Research Report on Systemic Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis BDB-001 injection, Cyclophosphamide, Glucocorticoids - ANCA-associated Vasculitis | Phase 1 / Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 93 | 2022-02-22 | 2025-08-07 |
| Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis. IFX-1, Placebo-IFX-1, Glucocorticoid (GC) - Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA) | Phase 2 | Completed | InflaRx GmbH | 57 | 2019-04-03 | 2022-08-25 |
| Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Naltrexone Hydrochloride, Placebo Comparator - Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS) | Phase 2 | Completed | University of Pennsylvania | 60 | 2019-02-04 | 2026-01-22 |
| Acquired Immunodeficiency in ANCA Associated Vasculitis Pneumococcal Polysaccharide Conjugate vaccination and Pneumococcal Polysaccharide Vaccination - Systemic Vasculitis | Phase 2 | Completed | Cambridge University Hospitals NHS Foundation Trust | 114 | 2018-10-15 | 2026-09-08 |
| Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy PCV13, PPV23, Rituximab - Invasive Pneumococcal Infection | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 96 | 2018-02-05 | 2025-11-20 |
| Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies Pirfenidone - Pulmonary Fibrosis | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 7 | 2018-01-31 | 2025-11-20 |
| Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids, CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids, Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids - ANCA-associated Vasculitis | Phase 2 | Completed | Amgen | 42 | 2015-02-04 | 2025-03-13 |
| Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases Interleukin 2 - Rheumatoid Arthritis, Ankylosing Spondylitis | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 81 | 2014-01-06 | 2021-07-20 |
| A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Rituximab - Granulomatosis With Polyangiitis | Phase 2 | Completed | Hoffmann-La Roche | 25 | 2013-05-23 | 2019-06-26 |
| Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome mepolizumab - Churg Strauss Syndrome | Phase 2 | Completed | University Hospital Schleswig-Holstein | 10 | 2008-07-01 | 2012-06-15 |
| Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis Abatacept - Wegener's Granulomatosis | Phase 1 / Phase 2 | Completed | University of Pennsylvania | 20 | 2008-02-01 | 2016-01-18 |
| Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome Mepolizumab - Churg Strauss Syndrome | Phase 1 / Phase 2 | Completed | Brigham and Women's Hospital | 10 | 2007-09-01 | 2017-03-22 |
| Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Rituximab plus cyclophosphamide placebo (rituximab group), Cyclophosphamide plus rituximab placebo (control group), Azathioprine - Vasculitis, Wegener's Granulomatosis | Phase 2 / Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 197 | 2005-01-01 | 2017-04-21 |
| Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis Gusperimus - Wegener's Granulomatosis | Phase 2 | Completed | Nippon Kayaku Co., Ltd. | 45 | 2003-12-01 | 2017-03-06 |
| Anti-Cytokine Therapy for Vasculitis Infliximab, Cyclophosphamide, Prednisolone - Wegener's Granulomatosis, Renal Limited Vasculitis | Phase 2 | Completed | University Hospital Birmingham NHS Foundation Trust | 37 | 2003-01-01 | 2008-09-16 |
| Daclizumab to Treat Wegener's Granulomatosis Daclizumab - Wegener's Granulomatosis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 75 | 2002-06-01 | 2008-03-04 |
| Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis Rituximab - Systemic Lupus Erythematosus, ANCA Associated Vasculitis | Phase 2 | Completed | Cambridge University Hospitals NHS Foundation Trust | 20 | 2002-03-01 | 2006-02-17 |
| Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Mepolizumab - Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis | Phase 1 / Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 24 | 2001-12-01 | 2020-07-29 |
| Etanercept for Wegener's Granulomatosis Etanercept - Wegener's Granulomatosis | Phase 2 / Phase 3 | Completed | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 181 | 2000-06-01 | 2007-12-28 |
| Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes Mycophenolate Mofetil - Vasculitis, Wegener's Granulomatosis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 75 | 2000-02-01 | 2008-03-04 |
Showing 20 of 25. Sign in to see all of them.
Granulomatosis with Polyangiitis (15) · Vasculitis (12) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (6) · Microscopic Polyangiitis (6) · Churg-Strauss Syndrome (4) · Recurrence (3) · Glomerulonephritis (2) · Inflammation (2) · Lupus Erythematosus, Systemic (2) · Polyarteritis Nodosa (2) · Aortic Arch Syndromes (1) · Arthritis, Rheumatoid (1) · Behcet Syndrome (1) · Cholangitis, Sclerosing (1)
Cardiovascular Diseases (25) · Skin Diseases (24) · Skin Diseases, Vascular (24) · Skin and Connective Tissue Diseases (24) · Vascular Diseases (24) · Autoimmune Diseases (23) · Immune System Diseases (23) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (17) · Lung Diseases (16) · Respiratory Tract Diseases (16) · Lung Diseases, Interstitial (15) · Vasculitis (13) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8)
Cyclophosphamide (6) · Rituximab (5) · Prednisone (4) · Glucocorticoids (3) · mepolizumab (3) · Azathioprine (2) · Etanercept (2) · Methylprednisolone (2) · Mycophenolic Acid (2) · Pneumococcal Vaccines (2) · 13-valent pneumococcal vaccine (1) · Abatacept (1) · BDB001 (1) · Control Groups (1) · Daclizumab (1)
National Institute of Allergy and Infectious Diseases (NIAID) (6) · Assistance Publique - Hôpitaux de Paris (3) · Cambridge University Hospitals NHS Foundation Trust (3) · University of Pennsylvania (2) · Amgen (1) · Brigham and Women's Hospital (1) · Children's Hospital Medical Center, Cincinnati (1) · Hoffmann-La Roche (1) · InflaRx GmbH (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Nippon Kayaku Co., Ltd. (1) · Staidson (Beijing) Biopharmaceuticals Co., Ltd (1) · University Hospital Birmingham NHS Foundation Trust (1) · University Hospital Schleswig-Holstein (1)
United States (14) · United Kingdom (6) · France (5) · Germany (4) · Canada (3) · Netherlands (3) · Czechia (2) · Italy (2) · Sweden (2) · Belgium (1) · China (1) · Denmark (1) · Russia (1) · Serbia (1) · Spain (1)
David Jayne (2) · John H. Stone, MD, MPH (2) · Peter A. Merkel, MD, MPH (2) · Anja Pfaff, PhD (1) · Carol A. Langford, MD, MHS (1) · Caroline OS Savage (1) · Jonathan London, MD (1) · Ken Smith (1) · Kirsten de Groot (1) · Lorraine Harper, PhD (1)
PMID 12905485, PMID 15751091, PMID 15838068, PMID 15986348, PMID 16378799, PMID 16646004, PMID 19451574, PMID 20647199, PMID 22127969, PMID 22975753, PMID 23754238, PMID 23902481, PMID 24323392, PMID 25047592, PMID 25776953, PMID 26387933, PMID 26621483, PMID 27696762, PMID 28592297, PMID 30472651, PMID 31216123, PMID 33128347, PMID 34164952, PMID 34618687, PMID 35279811
2016 (1), 2017 (1), U54AR057319 (1)